In a remarkable achievement, the Global Heterozygous Familial Hypercholesterolemia (HEFH) Management Industry is poised to reach new heights, projecting a valuation of US$ 15.11 billion in fiscal year 2023, a significant increase from US$ 13.2 billion in fiscal year 2022. The market’s upward trajectory is further substantiated by a forecasted consistent compound annual growth rate …